, , ,









Great little Company, looking like it is through its growing pain stage, onwards and upwards

********************************************************************

Scancell Hlds
Patent Approval
RNS Number : 0217Z
Scancell Holdings Plc
09 March 2012


9 March 2012





Scancell Holdings plc

("Scancell" or "the Company")

ImmunoBody® Patent Approved in US



Scancell Holdings plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that its protein ImmunoBody® vaccine patent has been approved in the United States. The patent, which has already been approved in Europe and Australia, will further strengthen Scancell's IP position around its proprietary ImmunoBody® vaccine platform.



Scancell's lead vaccine, SCIB1 is being developed for the treatment of melanoma and is currently in Phase I clinical trials. It is an innovative DNA vaccine being developed using Scancell's ImmunoBody® technology. Phase 2 trials are due to start in Q2 2012.



Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:



"The USA remains the most important market in which to commercialise our ImmunoBody ® vaccines. The award of this US patent confirms the innovative nature of the ImmunoBody ® platform and provides a sound basis on which to commercialise the technology in the US. Scancell will continue building its growing portfolio of intellectual property in parallel with driving the clinical trial programme forward during 2012

*******************************************************************

Especially......
Dr. Richard Goodfellow, Joint Chief Executive of Scancell, commented:



"The USA remains the most important market in which to commercialise our ImmunoBody ® vaccines. The award of this US patent confirms the innovative nature of the ImmunoBody ® platform and provides a sound basis on which to commercialise the technology in the US. Scancell will continue building its growing portfolio of intellectual property in parallel with driving the clinical trial programme forward during 2012


This is why all the excitement here.

Courtesy of the poster brigadon on LSE.


Make That A Billion Dollars!

After years of developing the melanoma antigens TRP - 2 and gp100 at the National Cancer Institute in Bethesda, Maryland, the United States Department of Health and Human Services (HHS) has entrusted Scancell with their commercial development. These antigens now form key components in the company's lead vaccine to treat melanoma, SCIB1.

The US Public Health Service, a division of HHS is due royalty payments on these antigens from future sales of SCIB1 so, to help realise a speedy return on its investment, the US National Institutes of Health, an agency of the US Department of Health has made the clinical trials data for SCIB1 available on its website, an important port of call for large pharmaceutical companies looking for new drugs and drug development businesses to acquire. [Scancell's board has expressed the intention to seek a 'trade sale' of the business upon completion of Phase II clinical trials of its lead vaccine SCIB1.]

In a recent presentation to analysts and investors Scancell made the point that large pharmaceutical companies were prepared to pay up to a billion dollars for a clinical stage cancer vaccine firm, such as Scancell, which had shown evidence of patient recovery from terminal forms of the disease after treatment with its products. In May 2010 it was revealed that an earlier version of SCIB1, configured at the time to treat bone cancer had indeed appeared to have cured two young patients of a terminal form of this condition.

It is this pedigree of Scancell's curative success, the watertight protection of its patents and the influential backing of the US Department of Health that any potential bidder will be buying into. So even if we were to assume the price being offered for Scancell, was only half of what has been offered in similar circumstances this could still amount to to an offer price of around 162p per share! Whatever the final price, it will certainly amount to many multiples of today's market price. I am therefore maintaining my Strong BUY recommendation for this stock.

Final Results

Highlights during the period:

· In July 2011, Scancell raised £1.58 million, net of expenses, by way of a placing of new shares

· New lung cancer vaccine, SCIB2 - latest anti-tumour results in animal models provide further validation of ImmunoBody® vaccine technology platform and its commercial potential

· In November 2011, received milestone payment from Arana Therapeutics of £2.49 million net of costs

· Completion of recruitment to Phase 1 of the clinical trial for SCIB1 in April 2012

· Profit for the year of £557,058 (2011:loss £1,649,225)

· Cash at year end £3,529,007 (2011: £1,110,630)

Post period highlights:
· On 15 August, 2012 Scancell announced the development of a new platform technology, ModitopeÔ, that stimulates the production of killer CD4 T cells with powerful anti-tumour activity.

Share Nominees Ltd > 9%

SCIB1 Trial-Higher Dose Allowed in Phase 1/2 Trial

Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that the Gene Therapy Advisory Committee ('GTAC') and the Medicines and Healthcare products Regulatory Agency ('MHRA') Medicines Division have given their approval to dose an extra group of patients with a higher, 8 mg, dose of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma.

The new cohort will recruit up to six more patients and will be recruited in parallel with the patients being recruited into Part 2 of the study. Patients with metastatic tumour present may enter the new cohort so that their tumour response can be assessed, whereas patients who have had their tumours surgically removed may enter Part 2. In addition, Scancell's partner Ichor Medical Systems ('Ichor') has obtained the required parallel approval from the MHRA Devices Division for the use of Ichor's TriGrid™ electroporation delivery device to administer SCIB1 to this additional group of patients."

Scancell is planning to start treating patients with the 8mg dose in the new year.

Update on patient recruitment in clinical trial

Update on patient recruitment in the ongoing SCIB1 clinical trial


Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, today announces the recruitment and treatment of the final patient in the second part of its Phase 1/2 clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. This part of the trial is being conducted in five UK centres in patients with Stage III/IV disease to further assess the safety of treatment and to assess the cellular immune response induced by SCIB1. Patients are being treated with a 4mg dose of SCIB1 on five occasions over a period of 6 months.

In December 2012, Scancell released preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma. Also in December 2012, Scancell announced that the Gene Therapy Advisory Committee ('GTAC') and the Medicines and Healthcare products Regulatory Agency ('MHRA') Medicines Division had given their approval to dose an extra group of patients with a higher, 8 mg, dose of SCIB1. Scancell is planning to start treating patients with the 8mg dose shortly.

Half Yearly Report

Highlights

· Encouraging preliminary results from Part 1 of the Phase 1/2 clinical trial for SCIB1 announced in December 2012

· First evidence that the vaccine is producing an immune response in cancer patients which may also be associated with clinical benefit

· Approval received to dose an extra group of patients with a higher, 8mg, dose of SCIB1

· Recruitment and treatment of the final patient in the second part of its Phase 1/2 clinical trial of SCIB1

ImmunoBody® Patent Approved for Grant in Japan.

Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, is pleased to announce that a patent for its protein ImmunoBody® vaccine technology has been approved for grant in Japan. The patent has already been approved in the US, Europe and Australia.

SCANCELL CHALLENGES THE NINE HUNDRED

Currently there are around 900 cancer vaccines in various stages of clinical trials. These 900 candidates represent a series of diverse approaches to the production of therapeutic cancer vaccines. Some include genetically engineered oncolytic viruses. Some include entire immune system transplants. Some include cancer antigens extracted from patients' urine, purified and mixed with alum. Some try to get away with a single antigen to treat all types of cancer; the so called universal approach. And some mix cancer antigens with the pulverized cell walls of bacteria to spark an immune response that way. But it is widely acknowledged that the most effective therapeutic cancer vaccines so far have been those which get patients' dendritic cells to absorb or retain on their surface cancer antigens specific to the particular cancer being treated. Scancell makes these latter kind of vaccines, called dendritic cell vaccines.

To date a number of companies have demonstrated that they can target dendritic cells ex vivo (outside the patient's body; having extracted them from the patient first) but only Scancell has been able to produce vaccines capable of targeting dendritic cells in vivo (while they are still in the patient's body).

So far only one company's vaccine has been approved by the FDA for commercial use. This company is the Dendreon Corporation and their vaccine is of course a dendritic cell vaccine. But it has one severe limitation. It can only target dendritic cells ex vivo by extracting them from each patient, before treating the cells for reinfusing back into the same patient again; a process which is inconvenient and prohibitively expensive. Scancell's one batch treats all approach therefore poses a serious threat to Dendreon's dominance of the global therapeutic cancer vaccine market. Hence the remarkable growth of Scancell's share price.

This is what Scancell says about its technology:

"A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive."


Research link:
http://www.scancell.co.uk/Apps/Content/html/?fid=6

SCANCELL SPELLS OUT THE LIMITATIONS OF ITS RIVALS

Cancer vaccines represent a highly attractive approach to cancer therapy. In contrast to current treatments such as chemotherapy and radiotherapy, small non-toxic doses of a vaccine may be administered to a patient to stimulate an immune response. It is generally accepted that to be effective against cancer, a vaccine needs to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system (known as the CD4-mediated response) which stimulates inflammation at the tumour site; and the cytotoxic T-lymphocyte or CTL response (known as the CD8-mediated response) in which cells of the immune system are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive.

Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome the present limitations of cancer vaccines.

Research link:
http://www.scancell.co.uk/Apps/Content/html/?fid=6

SCANCELL'S SKIN CANCER VACCINE TRIAL RESULTS

Here is a useful and informative post from Alan Turing, a poster with a good scientific background who writes on LSE's Scancell Chat. He is commenting on the recent Phase 1 results for Scancell's lead vaccine to treat melanoma, SCIB1:


PHASE 1 PRELIMINARY RESULTS

Well they were pretty astonishing really. Firstly because they were only measuring a group of patients in a study to test for toxicity, so there were only a few patients who actually received the vaccine at full strength.

The key 'stand out' was the tumour shrinkage in the patient with lung metastases. Dendritic cell vaccines have never before shrunk tumours without a toxic additive. Gp100 for instance was the first dendritic cell vaccine that was said, with much fanfare, to shrink tumours but only with the addition of the highly toxic Interleukin 2 (which defeats the purpose of using a non-toxic dendritic cell vaccine in my book). But previously without this additive Gp100 showed no signs of being able to shrink tumours. This is the most important achievement so far by SCIB1. It now has to repeat this in the proposed 8mg dose trial. If this tumour shrinking capability is confirmed then SCIB1 will have outdone all previous dendritic cell vaccines.

This extra power may be a result of its DNA delivery. The ImmunoBody vaccine consists of strands of DNA which are like a computer program. This DNA program is processed by the patient's healthy cells very much like a computer. Tens of thousands of antibodies are produced by the patient as instructed by Scancell's DNA program. Each antibody is shaped like a Y and on one of the arms of the Y is a 'pretend' cancer chemical unique to the cancer being treated. These antibodies, which in SCIB1's case, 'smell' like melanoma, stick to the surface of the immune system's sentinel cells (dendritic cells). They go crazy. To them they are covered in a foreign material that should definitely not be there. They then charge in their thousands to warn the immune system that something foreign has entered the body that needs to be searched for and destroyed. The immune system's army of T cells is dispatched. First the sappers, the Helper T-cells. They find the tumours and mark out a killing zone and change the blood chemistry inside this zone to make the tumours easier to kill. Then come the commandos, the Killer T-Cells to burst and destroy the tumours there.

This is so far ahead of what Dendreon does, Scancell's main competitor, that I suppose its no wonder that it achieved these promising results, albeit in just one particular patient. All eyes should be on the upcoming 8mg tumour trial, because so far, apart from its non-patient specific capability, the ability to shrink and eradicate tumours unaided is Scancell's most thrilling achievement. They have the pharmaceutical industry's attention for sure. Now they must show that they can repeat this success. I'm looking forward to the next instalment.

The market potential for dendritic cell vaccines is considerable. Scancell's vaccine is the only DNA (non-patient specific) version that has been shown to elicit an immune response. So if I was a buyer for a large pharmaceutical company looking for a dendritic cell vaccine to enter that sector of the market I would definitely choose Scancell's product first. The ability to shrink tumours is a unique one among this class of therapuetics so whatever this vaccine achieves on that front would be a bonus.

Bullrunner - thanks for the above post.

I looked at DNDN last summer before deciding to opt for SCLP - the former are also on a bit of a run recently and are ISA'ble.

SCANCELL'S RISE IS DENDREON'S DOOM!

The Dendreon Corporation is the one and only global leader in therapeutic cancer vaccines. The technology they use requires extracting immune system alarm cells (dendritic cells) from the patient's blood, pulsing them with cancer antigens and injecting them back into that same patient. This has proved prohibitively expensive. Scancell therefore designed an alternative solution and has provided the industry and the regulatory authorities with a more commercially viable product: a DNA dendtritic cell vaccine which coats the alarm cells with epitopes of cancer antigens while those alarm cells are still in the patient's body. This provides a solution with no rejection problems and can therefore be given to any number of patients without having to manufacture a fresh batch.

Dendreon's Provenge, to treat prostate cancer, is the first and only therapeutic cancer vaccine commercially approved to date but the business model behind it is fatally flawed and the industry knows it. The treatment is simply unaffordable. So as Dendreon's stock has plummeted, Scancell's stock has risen, making Scancell London's best performing stock of 2012. Without doubt Scancell remains the most significant ongoing threat to Dendreon's dominance.

Research link:
Scancell's ImmunoBody® Vaccines

SELLING THE KEYS TO THE KINGDOM

Scancell has a very simple strategy. Produce a better cancer vaccine than the global leader and sell Scancell on to the highest bidder by the end of the year.

So far only one company has had a therapeutic cancer vaccine approved for commercial use by the FDA. The Dendreon Corporation. Dendreon is therefore the one and only global leader in therapeutic cancer vaccines. But each treatment uses the blood of the patient to prepare it, so because of rejection, can only be given to one person at a time. This is inordinately expensive. So Dendreon's business model has proved to be fatally flawed with each course of treatment costing more than $90,000!

Scancell has found a way round this. It has patented a technology capable of providing the same treatment without having to extract the patient's blood first. Scancell's DNA vaccine can be given to any number of patients from the same batch so is therefore more cost effective, leaving plenty of room for profit.

In other words Scancell has found a short cut to becoming 'King of the Hill.' Whoever buys Scancell and brings its vaccines to market will become straight away the global leader of the cancer vaccine market. That's what's on offer. The keys to the kingdom. And in the expected bidding war to come, that's what will be fought over.

The Intellectual Property of Scancell's skin cancer vaccine, SCIB1, alone has been valued at a billion dollars! But Scancell's DNA vaccine technology allows its vaccines to be reprogrammed to treat different cancers. In fact, any kind of cancer. Indeed its already started the ball rolling for whoever buys Scancell by pre-preparing a second vaccine to treat lung cancer.

The industry will pay at least £12 a share (around $4 billion) for Scancell's existing vaccines in combination with its reprogrammable vaccine platform. They wont be able to resist it. If a company doesn't buy Scancell they hand over to the competition the top global position in cancer vaccines for a generation. A wise person will know that no pharmaceutical company can stand by and let that happen! Four billion dollars will prevent such a disaster. For they will fight like dogs to get Scancell. And as they do, its shares will rise and rise. In the end they could climb even higher than £12.



Research link:
Scancell's ImmunoBody® Vaccines

Scancell reveals plan to target rival's lead vaccine

Its no secret that Scancell has rival manufacturer Dendreon firmly in its sights. Dendreon holds the coveted position as leader of the therapeutic cancer vaccine market but not for long if Scancell has its way.

Dendreon has been a true trail blazer and its founders were the brains behind the only type of therapeutic cancer vaccine to get commercial approval by the FDA, the dendritic cell vaccine. Non-toxic and cleverly marshalling the patient's own immune system to fight off the disease, they thought they had it made when their first vaccine to treat prostate cancer entered the market place. Their science which used the immune system's sentinels, the dendritic cells, to alert the immune system to the presence of cancer was truly ground breaking but the technology they devised to produce their vaccine was simply uneconomic. Patients had to have their blood collected and sent off to Dendreon so their dendritic cells could be extracted, primed with cancer proteins to allow the immune system to identify and hunt down the cancer and returned for re-infusing back into the patient again. So every batch had to be 'tailor made' for just one patient! It cost the proverbial arm and a leg. $93,000 for a course of treatment that never really worked at its best because of the damage the patient's dendritic cells suffered in the process.

But the real nightmare for Dendreon began when Scancell came up with an alternative dendritic cell vaccine that didn't need patients' blood to make it. In fact Scancell's vaccine actually coated a patient's dendritic cells with cancer proteins while they were still in the patient's body; outdoing Dendreon's expensive 'one patient at a time' vaccine with one that could be mass produced to treat millions of patients from a single batch!

Scancell has achieved this by designing a DNA cancer vaccine called ImmunoBody that instructs the patient's own cells to produce special antibodies which mimic cancer proteins and stick to the surfaces of the patient's dendritic cells. The alarm is raised and the immune system seeks out and destroys the cancer these special antibodies are mimicking. Scancell's vaccine is also re-programmable, enabling it to target any kind of cancer by simply altering its DNA program to cause the production of antibodies that mimic the proteins of a different type of cancer.


The conference that time forgot
As far as most commentators knew Scancell was working on just two ImmunoBody vaccines, SCIB1 to treat melanoma, which is currently in Phase 2 clinical trials and SCIB2 to treat lung cancer which is now ready for trialling. So until last weekend, Dendreon could have comforted itself with the notion that Scancell was swimming in its neighbours' pools. But owing to the diligent research and dogged inquiry of a poster on London South East Scancell Share Chat, Inanaco, Scancell has revealed that they are working on a new ImmunoBody vaccine to treat prostate cancer as well! This has to be Dendreon's worst nightmare.

This astonishing news was initially 'leaked,' but went largely unreported, in a 15 minute presentation at the 12th International Conference on Progress in Vaccination Against Cancer (PIVAC) on Wednesday 12th September 2012. The paper entitled, "Development of new prostate cancer vaccine strategies using PAP as target antigen," described a collaborative project between Scancell and researchers at Nottingham Trent University.

The paper doesn't mince its words. It makes it abundantly clear that the intention is to use Scancell's ImmunoBody DNA vaccine technology to make a mass market successor to Dendreon's only commercial product, its prostate cancer vaccine Provenge. SCIB3, as it will no doubt be called, will encode epitopes from the same antigen used in Provenge. But even more alarmingly for any of Scancell's competitors in the prostate cancer field, Scancell seems to be preparing a prophylactic prostate cancer vaccine as well, intended to prevent the disease developing in the first place. And if you don't think that Scancell are serious about this just take a look at what Professor Lindy Durrant said about Scancell's SCIB 1 vaccine as long ago as May 2010:

"In the short term, this could cure some patients with the disease, and in the long term it could be used to prevent people developing it in the first place."


A weekend of revelations
Having come across the above research in PIVAC's conference program, Inanaco sent an email to Scancell seeking clarification of their apparent intentions to develop a vaccine to treat prostate cancer. These intentions were then confirmed in an email from the company which was then posted by Inanaco on London South East's Scancell Chat last Sunday afternoon at 16:10. It read:


Hi *****

You certainly are diligent in your research!! This is early stage research on a possible new ImmunoBody for prostate cancer. We also have several others in development but do not normally make any announcements until we have developed the vaccine to the point where it is sufficiently advanced to be considered a candidate already ready for clinical development (such as SCIB2)

Kind regards

Richard


So Dendreon, you have been warned, but there is precious little you can do about it anyway. Scancell is technologically so far in advance of any other company producing dendritic cell vaccines that its competition might be best advised to prepare for the inevitable. What's that I hear, "Scancell's just a tiny British company with a few million dollars in the bank?" Think again, at the end of this year Scancell is going to be offered up for sale to the highest bidder. The directors have already told the press that they have been approached by suitors so its only a matter of time until the big boys get hold of Scancell's breakthrough DNA technology. Then it really will be curtains for Dendreon.







Research link:

Latest interview by ceo richard goodfellow on 27th feb 2013 at the frankfurt stock exchange, uploaded 7th march 2013.

http://www.youtube.com/watch?v=E-J5J7bBQDs

Scancell welcomes new study in The Journal of Clinical Investigation suggesting that melanoma switches off the immune system


Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, would like to alert shareholders to the recent article "IgG4 subclass antibodies impair antitumor immunity in melanoma" in the peer reviewed cancer journal: The Journal of Clinical Investigation, published on 1 March 2013.

The new study published in The Journal of Clinical Investigation supports earlier studies by King's College London that indicate that patients with the cancer, malignant melanoma, appear to elicit a weak antibody response to the tumour cells which appears to be relatively ineffective in combating the cancer and which may in effect switch off the immune system.

This study indicates that patients with malignant melanoma initiate a B cell immune response to produce an antibody called IgG4. IgG4 is considered a "weak" subclass of antibody and is thought to inhibit the production of other stronger antibodies such as IgG1, actually protecting the tumour cells from a more effective and aggressive attack from the patients' immune system.

Scancell's melanoma cancer vaccine SCIB1, which is currently in Part 2 of a Phase I/II clinical trial, works by activating the immune system through T cells rather than B cells. The Board believes that T cell activation is a more effective approach to treating patients with an immune system compromised in the manner found in those with malignant melanoma.

Dr Richard Goodfellow, joint Chief Executive Officer of Scancell, comments: "We believe that The Journal of Clinical Investigation paper supports Scancell's approach to fighting cancers, such as malignant melanoma, where T cell activation appears to be the more effective route of combating this often fatal disease. Results from our Phase I/II clinical trial are expected at the end of this year."


-ENDS-

Appoints Peter Allen as Non-Executive Director

Scancell Holdings Plc, (AIM:SCLP), the developer of therapeutic cancer vaccines, today announces that Peter Allen, ACA, has been appointed to the Board as Non-Executive Director, with immediate effect.

Peter has had a distinguished career in the life sciences industry. A chartered accountant by profession, he has held key senior positions in a number of companies, playing a significant role in their development. His experience extends to overseeing and orchestrating fundraisings, restructurings, acquisitions and IPOs. Peter has also had extensive M&A experience including the acquisitions of Chiroscience, Medeva and Oxford Glycosciences during his 12 year tenure at Celltech as CFO and Deputy CEO, which concluded in its £1.5 billion sale to UCB in 2004. More recently, as Chairman at Proximagen, Peter played a fundamental role in its acquisition by Upsher-Smith Laboratories for £357 million in 2012 and whilst Chairman and interim CEO of Prostrakan, he oversaw the sale of the Company to Kyowa Hakko Kirin for £292 million in 2011.

Peter is currently Chairman of Clinigen PLC, Chroma Therapeutics Limited, ProStrakan plc and Future plc and a non-executive Director of Oxford Nanopore Technologies Limited.

Strong today on reasonable volume.

Are we already in play??????

Posted by Puritas on a competitors bb....

Although Scancell plans to sell to the highest bidder in six months time will bidders wait that long?

When my cupboards bare I go out to the supermarket to stock up, no messing!

Big Pharma's out of patented stock and they ain't messing either!

Two Scancell sized companies have been snaffled up in the space of six days! On June 11th AstraZeneca nabbed Pearl, for its obstructive lung disease inhaler, fresh out of Phase II. Then on June 17th Johnson & Johnson acquired Aragon Pharmaceuticals for its lead drug to treat prostate cancer still in Phase I/II.

Pearl got a $1.15 billion deal for a single drug to treat just one type of lung disease and Aragon got its billion dollar deal for its androgen receptor inhibitor that's no further along the line than Scancell's SCIB1 vaccine is now!

Clearly the big boys don't wait for an invite to come knocking. And when time is such serious money for big pharma, six long months of lost future sales may be a spur to immediate action.

Alls peaceful, as tactics are discussed at Scancell manor.
Then an ear shattering, "RAT TAT TAT TAT!"

Yes, that Scancell sized company on next week's shopping list might very well be Scancell itself. And Scancell has a darn sight more product to fill up big pharma's trolley than either Pearl or Aragon could offer!

Rodders

Trying to stay above 50p having hit 6 month+ highs.

Final Results

Highlights during the period:

· Successful completion of Part 1 of the SCIB1 Phase 1/2 clinical trial
· Part 2 of the SCIB1 Phase 1/2 clinical trial fully recruited and on track for completion by the end of 2013
· Additional 8mg dose study underway, also expected to be completed by the end of 2013
· Development of new Moditope™ platform
· Strengthened IP with patents awarded in the US and Japan for protein Immunobody® technology platform
· Peter Allen appointed as a Director

Post period highlights:

· Placing and Open offer up to £6.5 million (announced today)

Proposed Firm Placing and Open Offer